News | June 16, 2009

MDS Nordion to Partner With Russian Medical Isotope Supplier

June 16, 2009 - MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals used in molecular medicine, and the Karpov Institute of Physical Chemistry in Moscow, Russia, have agreed to study the feasibility of the Karpov Institute providing the company with a flexible, reliable and responsive medical-isotope supplier of molybdenum-99 (Mo-99) for the global nuclear medicine market.

MDS Nordion and the Karpov Institute have agreed to combine their respective expertise and resources to explore the development of a commercialization plan to address a portion of the need for a long-term supply of moly-99.

Together, MDS Nordion and the Karpov Institute have strong technical and operational expertise. MDS Nordion has substantial technical and marketing knowledge; the Karpov Institute brings substantial nuclear infrastructure and expertise in physics and reactor operations.

The Karpov Institute of Physical Chemistry is classified as a State Scientific Centre, which has been involved in basic and applied research in the area of physical chemistry for more than 90 years. Production of medical isotopes and radiopharmaceuticals using the capabilities of the WWR-c research reactor is one of the most important multidirectional activities currently developed at the institute. The Karpov Institute is the main supplier (90 percent) of Mo-99 and Tc-99m generators to the domestic Russian market. Our products are delivered weekly to more than 200 clinics throughout Russia.

For more information: www.mdsnordion.com

Related Content

CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical...
Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017
April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt...
GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | April 05, 2017
April 5, 2017 — GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered
Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers | March 01, 2017 | Anamika Kumari
Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial r
News | Radiopharmaceuticals and Tracers | January 17, 2017
NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s National...
Overlay Init